Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Respiratory syncytial virus bronchiolitis.

Alexander K C Leung1, James D Kellner, H Dele Davies

  • 1Department of Pediatrics, University of Calgary, Alberta Children's Hospital, Canada. aleung@ucalgary.ca

Journal of the National Medical Association
|January 7, 2006
PubMed
Summary

Respiratory syncytial virus (RSV) causes bronchiolitis, a common reason for infant hospitalization and significant illness globally. Supportive care and hand-washing are key, with palivizumab offering protection for high-risk infants.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Incidence of Recurrent Invasive Pneumococcal Disease in Canada.

JAMA network open·2026
Same author

Expression and Correlation Analysis of Neuropeptide Family Members in the Peripheral Blood of Patients with COVID-19.

Current pediatric reviews·2026
Same author

A Narrative Review of Dietary Interventions and Supplementation for the Prevention and Treatment of Atopic Dermatitis.

Current pediatric reviews·2026
Same author

mRNA COVID-19 vaccine safety in adults from the Canadian national vaccine safety network.

Vaccine·2026
Same author

Safety of COVID-19 and influenza vaccines in children and adolescents with immunocompromised or autoimmune conditions: Findings from the Canadian National Vaccine Safety (CANVAS) network.

Human vaccines & immunotherapeutics·2026
Same author

Post-licensure safety of nirsevimab from the Canadian National Vaccine Safety (CANVAS) network.

Human vaccines & immunotherapeutics·2026

Area of Science:

  • Pediatrics
  • Infectious Diseases
  • Virology

Background:

  • Respiratory syncytial virus (RSV) is the primary cause of bronchiolitis, leading to widespread infant hospitalizations and considerable mortality/morbidity, especially in developing nations.
  • Nearly all children are infected by RSV by age two, with 80% of cases occurring in the first year of life.
  • Infants under six weeks, premature infants, and those with cardiopulmonary disorders or immunodeficiency face higher risks for severe RSV bronchiolitis.

Purpose of the Study:

  • To summarize the epidemiology, clinical presentation, and management of respiratory syncytial virus (RSV) bronchiolitis.
  • To highlight preventative measures and therapeutic options for RSV infection in infants.
  • To underscore the importance of supportive care and prophylactic interventions for high-risk populations.

Related Experiment Videos

Main Methods:

  • Review of existing literature on respiratory syncytial virus (RSV) and bronchiolitis.
  • Analysis of clinical manifestations, risk factors, and treatment strategies.
  • Evaluation of the efficacy of palivizumab for prevention in high-risk infants.

Main Results:

  • RSV bronchiolitis typically presents with cough, wheezing, and respiratory distress.
  • Supportive care, including hydration, fever management, and oxygen therapy, forms the primary treatment.
  • Meticulous hand-washing is crucial for preventing secondary transmission.
  • Palivizumab prophylaxis demonstrates effectiveness in preventing severe RSV bronchiolitis in at-risk infants.
  • The condition is generally self-limiting, with a mortality rate below 1%, primarily affecting high-risk individuals.

Conclusions:

  • Respiratory syncytial virus (RSV) bronchiolitis is a significant pediatric respiratory illness requiring prompt supportive care.
  • Preventative strategies, including hygiene and prophylactic palivizumab for high-risk infants, are vital.
  • While typically self-limiting, severe outcomes and mortality are associated with specific risk factors, necessitating individualized management.